'김갑성' 기자의 전체기사
-
More countries now require tobacco plain packaging and…
[ 메디채널 김갑성 기자 ] Canadian Cancer Society report highlights global progress on key tobacco control measures TORONTO, Nov. 18, 2025 -- An international report released today by the Canadian Cancer Society (CCS) reveals ongoing progress for tobacco plain packaging and graphic picture warnings worldwide. The CCS report, titled Cigarette Package Health Warnings: International Status Report, details global developments on plain packaging, ranks 212 countries and territories on the size of their health warnings on cigarette packages, and lists the 140 countries and territories that now requi
- 김갑성 기자
- 2025-11-18 13:01
-
Taiwan's CMUH Completes HIMSS "Grand Slam," Achieving DIAM St…
TAICHUNG, Nov. 18, 2025 -- China Medical University Hospital (CMUH) has secured one of the world's highest honors in digital health, becoming the first hospital in Taiwan to achieve Stage 7 certification under the HIMSS Digital Imaging Adoption Model (DIAM). The designation, awarded by the U.S.-based Healthcare Information and Management Systems Society (HIMSS), represents the pinnacle of excellence in medical imaging worldwide. With this achievement, CMUH has now completed the entire portfolio of HIMSS certifications, earning what hospital Superintendent Dr. Der Yang Cho described as
- 김갑성 기자
- 2025-11-18 09:01
-
INSTITUTE OF NEURODIVERSITY, NEUROPOWER WORLD, AND SINGAPORE BRI…
[ 메디채널 김갑성 기자 ] Hazleen Ahmad, Founder of Neuropower World and Chair & Founder of ION Singapore, to launch pilot projects and training programmes embedding neurodesign into workplaces, housing, parks, and transport hubs SINGAPORE, Nov. 18, 2025 -- The Institute of Neurodiversity (ION) Singapore and Neuropower World, dedicated to advancing inclusion and opportunities for neurominorities, hosted their first Neurodesign Roundtable — Re-thinking Urban Spaces: Designing Cities for Every Mind. The session brought together leaders from urban planning, business, and the community to expl
- 김갑성 기자
- 2025-11-18 09:00
-
MindHYVE's ChironAI™ Showcased at Peshawar Institute of Ca…
PESHAWAR, Pakistan, Nov. 18, 2025 -- The Peshawar Institute of Cardiology – Medical Teaching Institute (PIC-MTI) hosted a high-profile Radiology Continuing Medical Education (CME) session on "Innovations in Cardiovascular Imaging," drawing senior cardiologists, radiologists, and imaging specialists from across Pakistan for an exchange on cutting-edge developments in cardiac imaging and diagnostic technologies. As part of the CME program, Bill Faruki, Founder & CEO of MindHYVE.ai™, was invited to join the event for a live demonstration of ChironAI™ — MindHY
- 김갑성 기자
- 2025-11-18 08:50
-
Genesis MedTech and National University Health System Forg…
SINGAPORE, Nov. 18, 2025 -- Genesis MedTech Group and the National University Health System (NUHS) have formed a strategic partnership to advance artificial intelligence (AI) in surgery and medical device innovation. This partnership stems from a Memorandum of Understanding signed earlier this year, with further details unveiled at the World Congress of Endoscopic Surgery (WCES). As surgical challenges evolve, AI-driven technologies are enabling surgeons with data-driven insights to deliver safer, personalised and better outcomes for patients. At the same time, th
- 김갑성 기자
- 2025-11-18 08:00
-
Canary Speech Receives Frost & Sullivan's 2025 North America…
[ 메디채널 김갑성 기자 ] Recognized for transforming Intelligent Vocal Biomarker Diagnostics through innovative AI-powered, smartphone-based diagnostic solutions SAN ANTONIO, Nov. 17, 2025 -- Frost & Sullivan is pleased to announce that Canary Speech, a global leader in AI-powered vocal biomarker technology, has received the 2025 North America Technology Innovation Leadership recognition in the intelligent vocal biomarker diagnostics industry for its outstanding achievements in technology innovation. This recognition highlights Canary Speech's consistent leadership in driving measurable o
- 김갑성 기자
- 2025-11-17 23:00
-
Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publi…
Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, today announced it has been named the winner of the "Best ADC Preclinical Publication 2024" at the 12th Annual World ADC Awards, recognizing the company's innovative research publication on the AJICAP® linker technology. The honored
- 김갑성 기자
- 2025-11-17 22:26
-
Bambusa Therapeutics Announces Completion of Series A…
BOSTON, Nov. 17, 2025 -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its oversubscribed Series A-2 financing, closed at a substantial valuation step-up over the prior round. This Series A-2 financing reflects strong participation from Bambusa's existing investors, including Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners L.P., Salvia GmbH, Janus Henderson Investors, Inv
- 김갑성 기자
- 2025-11-17 22:15
-
Henlius and Organon Announce US FDA Approval of POHERDY®…
SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.[1] POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic thera
- 김갑성 기자
- 2025-11-17 22:06
-
Lunit and Labcorp Announce Strategic Collaboration to Ad…
DURHAM, N.C. and SEOUL, South Korea, Nov. 17, 2025 -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care. The collaboration aims to leverage Labcorp's extensive clinical and pathology expertise alongside Lunit's cutting-edge AI algorithms to transform how tumor microenvironments are analyzed and in
- 김갑성 기자
- 2025-11-17 22:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-12-10_WED
- DAR GLOBAL AWARDS ENABLING WORKS CONTRACT FOR TRUMP INTERNATIONAL HOTEL & TOWER, DUBAI TO EDRAFOR EMIRATES LLC 19:46
- Indonesia Must Accelerate Targeted Digital Investment to Move into APAC's Leading Tier of Digital Nations, says GSMA 19:42
- Yupp Video Services Powers Chaupal's Full-Scale Technology Upgrade, Strengthening Platform Reliability, Performance, and User Experience Across 25+ Devices 19:35
- CNFINANCE ANNOUNCES THE RESULTS OF ITS EXTRAORDINARY GENERAL MEETING 19:15
- 資本の首都から、ADFWが資産運用の次なるフロンティアを描く 18:58
- 이제 유니온페이 카드로 15개 국가에서 애플 서비스 온라인 결제 가능 18:46
- World Gym Corporation (2762.TW) Reports Robust November Revenue Growth and Unveils Ambitious 2026 Strategic Roadmap 18:30
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 12월 10일 21시 20분